Unicycive Therapeutics Class Action Shares Update and Alerts

Author: Logan Wright Updated: 09-25-2025 09:00 AM

Unicycive Therapeutics Class Action Lawsuit Update

The Gross Law Firm has important information for investors concerning Unicycive Therapeutics, Inc. (NASDAQ: UNCY), focusing on a current class action lawsuit. Shareholders who acquired UNCY shares within the specified class period are strongly encouraged to reach out to the firm for possible lead plaintiff considerations. It’s crucial to understand that being appointed as a lead plaintiff is not a prerequisite for taking part in any potential recovery.

Details for Shareholders

This class action involves shareholders who purchased shares from March 29, 2024, to June 27, 2025. If you bought your shares during this time frame, now is the time to consider your options.

Class Period and Allegations

The lawsuit alleges significant misstatements and omissions from the company during this class period. Specifically, it contends that Unicycive overstated its readiness to meet the FDA’s manufacturing compliance requirements and misrepresented the regulatory prospects of its oxylanthanum carbonate new drug application. This lack of transparency has purportedly rendered Defendants’ public statements materially false and misleading.

Deadline for Registration

The critical date for shareholders to take action is October 14, 2025. It’s advisable for anyone interested in participating in the class action to register promptly to ensure they don’t miss out on any potential claims. You may register your information through the designated form.

Next Steps for Involved Shareholders

Upon registration as a shareholder who purchased shares of UNCY within the outlined period, individuals will be integrated into a portfolio monitoring system. This system will keep you updated on the status throughout the litigation process. Again, the October 14, 2025 deadline for seeking lead plaintiff status is significant, but no costs or obligations are attached to your participation.

Why Choose Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized law firm committed to safeguarding the rights of investors affected by fraudulent and deceitful practices. Our aim is to hold companies accountable, ensuring adherence to responsible business operations. The firm is dedicated to pursuing recovery for investors experiencing losses due to misleading statements that artificially inflate stock prices. It’s essential to note that prior outcomes do not guarantee similar future results.

Contact Information for Support

If you have questions or need more details about the class action, please reach out to The Gross Law Firm located at 15 West 38th Street, 12th floor, New York, NY 10018. You can also call (646) 453-8903 for assistance. Email communication is welcome, although the email address is omitted here for security reasons.

Frequently Asked Questions

What is the class period for the Unicycive Therapeutics lawsuit?

The class period is from March 29, 2024, to June 27, 2025.

How can I register for the class action lawsuit?

Shareholders can register by submitting their information through the specified online form.

Is there a cost to participate in the class action?

No, there is no cost or obligation to participate in the class action.

What are the allegations against Unicycive Therapeutics?

The allegations primarily relate to misleading statements regarding the company's compliance with FDA regulations and the prospects of its new drug application.

Who can be a lead plaintiff in the class action?

Any shareholder who purchased shares during the class period can seek to be a lead plaintiff, but it is not necessary to participate in the case.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.